This study is looking at whether psilocybin (a drug) can be a practical treatment for people with Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease, who also experience depressed mood. The study will also explore how psilocybin might affect depression, quality of life, feelings of hopelessness, and daily function for these patients. Up to 24 participants will be enrolled. To join, you must be at least 18 years old, have a diagnosis of ALS, and have good lung function (forced vital capacity >60%). The main goal is to see if psilocybin treatment is feasible, meaning if people can be recruited, stay in the study, and follow the treatment plan. The current recruitment status is unclear.

Study design

This is an open-label study, meaning you and the researchers will know what treatment you are receiving. It's a single-arm study, so all participants will receive the psilocybin treatment. Up to 24 people are planned to join.

What's involved

You would complete an 8-week treatment course, including two psilocybin sessions. These sessions are planned for week 4 (15 mg) and week 6 (15 or 25 mg).

Compensation

Not stated in the trial record.

Follow-up

You will have follow-up assessments 1, 3, and 6 months after your last psilocybin session.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.